<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833413</url>
  </required_header>
  <id_info>
    <org_study_id>ZSE-202104</org_study_id>
    <nct_id>NCT04833413</nct_id>
  </id_info>
  <brief_title>Regimen Switch After Intensive Insulin Therapy</brief_title>
  <official_title>Effectiveness of Regimen Switch After Intensive Insulin Therapy in Hospitalized Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin intensive therapy have traditionally been considered a sequential therapy in type 2&#xD;
      diabetes last choice, a number of guidelines and consensus recommendations insulin intensive&#xD;
      therapy can be as obvious hyperglycemia in patients with newly diagnosed T2DM part of a line,&#xD;
      a subset of patients after insulin intensive treatment target often need to change to other&#xD;
      treatments, especially for senile diabetes patients, due to its self management ability,&#xD;
      simplify the insulin solution is more urgent. Current clinical guidelines do not provide&#xD;
      specific clinical guidance, such as the timing and method of switch after initial insulin&#xD;
      intensive therapy. The purpose of this study was to explore the timing, suitable population&#xD;
      and conversion methods of insulin regimens after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selecting initial insulin intensive therapy during the period of hospitalization in patients&#xD;
      with type 2 diabetes, collect the basic information and biochemical information collection,&#xD;
      including gender, age, duration of diabetes, intensive glucose-lowering treatment plan before&#xD;
      treatment, diabetes complications, merger disease, smoking, drinking, height, weight, blood&#xD;
      pressure, fasting glucose, glycosylated hemoglobin and glycosylated serum protein, insulin,&#xD;
      c-peptide, liver and kidney function, blood lipid, blood routine, hypoglycemia is happening&#xD;
      almost 1 month. Follow-up was conducted in January, March and June. Endocrinologists decide&#xD;
      whether to continue the original hypoglycemic regimen or adjust it according to the glycemic&#xD;
      control goals, islet β-cell function, diabetes complications, complications, hypoglycemia and&#xD;
      other combination drugs, as well as patients' treatment willingness and compliance. To&#xD;
      compare the timing of conversion of treatment regimens, the proportion of conversion to each&#xD;
      regimen and the situation of reaching the standard, and to further analyze and compare the&#xD;
      characteristics of people who switched to different regimens, in order to establish the basis&#xD;
      for the selection of adjustment regimens after insulin treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>1，3，6 months</time_frame>
    <description>HbA1c in different conversion regimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average blood glucose</measure>
    <time_frame>1，3，6 months</time_frame>
    <description>The average blood glucose in different conversion regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>1，3，6 months</time_frame>
    <description>Fasting blood glucose in different conversion regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood glucose</measure>
    <time_frame>1，3，6 months</time_frame>
    <description>Postprandial blood glucose in different conversion regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>1，3，6 months</time_frame>
    <description>Incidence of hypoglycemia in different conversion regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on body weight</measure>
    <time_frame>1，3，6 months</time_frame>
    <description>Impact on body weight in different conversion regimens</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Insulin</condition>
  <arm_group>
    <arm_group_label>Continue intensive treatment group</arm_group_label>
    <description>Patients with type 2 diabetes who continued intensive treatment within 6 months after hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed insulin treatment group</arm_group_label>
    <description>Patients with type 2 diabetes who changed to premixed insulin within 6 months after hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basic insulin treatment group</arm_group_label>
    <description>Patients with type 2 diabetes who changed to basic insulin treatment within 6 months after hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral hypoglycemic drug treatment group</arm_group_label>
    <description>Patients with type 2 diabetes who changed to oral hypoglycemic drug treatment within 6 months after hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous intensive insulin therapy</intervention_name>
    <description>After initial intensive insulin therapy in hospital, patients were grouped according to different treatment regimens within 6 months of discharge</description>
    <arm_group_label>Basic insulin treatment group</arm_group_label>
    <arm_group_label>Continue intensive treatment group</arm_group_label>
    <arm_group_label>Premixed insulin treatment group</arm_group_label>
    <other_name>Premixed insulin therapy</other_name>
    <other_name>Basic insulin therapy</other_name>
    <other_name>Oral hypoglycemic drug therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        2021.4 -- 2022.6 Adult patients with type 2 diabetes admitted to the endocrinology&#xD;
        department of a level-2 or higher hospital and initiated intensive insulin therapy during&#xD;
        hospitalization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes;&#xD;
&#xD;
          -  Patients who started intensive insulin therapy during hospitalization&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes, special type diabetes&#xD;
&#xD;
          -  Acute complications of diabetes (diabetic ketoacidosis, hyperglycemia and&#xD;
             hyperosmolarity)&#xD;
&#xD;
          -  Severe infection&#xD;
&#xD;
          -  pregnancy or planned pregnancy&#xD;
&#xD;
          -  Participating in other clinical studies or trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiao ying Li, MD</last_name>
    <phone>13651913857</phone>
    <email>xiaoying_li@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Chen, MD</last_name>
    <phone>15351890068</phone>
    <email>baiyuan9873@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao ying Li, MD</last_name>
      <phone>13651913857</phone>
      <email>xiaoying_li@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Juan yu Fan, MD</last_name>
      <phone>18101947845</phone>
      <email>fanyujuan22@sohu.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinoogy, Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujuan Fan</last_name>
      <phone>18101947845</phone>
      <email>fanyujuan22@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Home PD, Dain MP, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res Clin Pract. 2015 May;108(2):350-9. doi: 10.1016/j.diabres.2015.01.030. Epub 2015 Jan 23.</citation>
    <PMID>25825361</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, Jang HC, Park SW, Lee KW, Won KC, Kim YI, Chung CH, Park TS, Lee JH, Lee MK. Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial. J Diabetes. 2016 May;8(3):405-13. doi: 10.1111/1753-0407.12312. Epub 2015 Jun 29.</citation>
    <PMID>25952532</PMID>
  </results_reference>
  <results_reference>
    <citation>Weng J. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c &gt; 9. J Diabetes. 2017 Oct;9(10):890-893. doi: 10.1111/1753-0407.12581. Epub 2017 Aug 22.</citation>
    <PMID>28661564</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033. Epub 2018 Oct 4.</citation>
    <PMID>30291106</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, Casal F, Delgado E, Menendez E, Umpierrez GE. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. Diabetes Care. 2015 Dec;38(12):2211-6. doi: 10.2337/dc15-0160. Epub 2015 Oct 12.</citation>
    <PMID>26459273</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017 Aug;19(8):1155-1164. doi: 10.1111/dom.12927. Epub 2017 Apr 10.</citation>
    <PMID>28251792</PMID>
  </results_reference>
  <results_reference>
    <citation>Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018 Mar;20(3):488-496. doi: 10.1111/dom.13132. Epub 2017 Nov 22. Review.</citation>
    <PMID>29053215</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017 Jul;40(7):951-957. doi: 10.2337/dc16-1770. Epub 2017 May 8.</citation>
    <PMID>28483786</PMID>
  </results_reference>
  <results_reference>
    <citation>Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahrén B, Torffvit O, Attvall S, Ekelund M, Filipsson K, Tengmark BO, Sjöberg S, Pehrsson NG. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015 Oct 28;351:h5364. doi: 10.1136/bmj.h5364.</citation>
    <PMID>26512041</PMID>
  </results_reference>
  <results_reference>
    <citation>American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220. doi: 10.2337/dc21-S015. Review.</citation>
    <PMID>33298426</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 3, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical study Report may be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

